Press Releases

Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx

Merck, known as MSD outside the United States and Canada, today confirmed terms of an agreement with plaintiffs to resolve Plubell v. Merck, an economic class action lawsuit pending in Missouri state court. The...

Genzyme Announces Publication of LEMTRADATM (alemtuzumab) Pivotal Studies in The Lancet

Genzyme, aSanofi company , announced today the publication of results from the LEMTRADA™ (alemtuzumab) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis (MS) in the November 1, 2012 online issue of The Lancet....

Adocia announces the strong growth of its turnover

Adocia , a biotechnology company specialized in the development of ‘best-in-class’ medicines with already approved therapeutic proteins, announces today revenues for the third quarter of 2012 and revenues for the nine month period to the end of September....

Ariana(R) Pharma and CTCLS sign Japanese distribution agreement for data analysis technology

Ariana Pharma, the premium provider of advanced, non-statistical clinical data and biomarker analytics technology across life science industries as well as the FDA, today announces the signing of an exclusive Japanese distribution agreement with CTC Laboratory Systems Corporation (CTCLS),...

TxCell announces publication of CATS1 study results for antigen-specific Treg therapy in Crohn¹s disease in Gastroenterology

TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces today the publication of the complete results of CATS1 Crohn’s disease study in Gastroenterology, the most...

Cytheris announces US Orphan Drug Designation for CYT107 for the treatment of Progressive Multifocal Leucoencephalopathy (PML)

Cytheris SA, a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announces today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation for Cytheris’ CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the...

Domain Therapeutics enters into collaboration agreement with Ono in the field of GPCR-based drug discovery

Domain Therapeutics S.A. announced today that Domain Therapeutics and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration agreement focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs).  Under the agreement, Ono will...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read